Company also reaffirms data readout timelines for its Phase 2 trial VICTORIA, BC – Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug… Read More
Free, Live, 90-minute Medical Device Playbook Event on Thursday, September 23, 2021. Francois Michelon, CEO, ENDRA Life Sciences, and Steven Plymale, Former CEO, MyndTec and Profound Medical, discuss lessons learned… Read More
Acquisition expands AbCellera’s existing capabilities to unlock difficult-to-drug transmembrane proteins for antibody discovery programs VANCOUVER, British Columbia & BOSTON – (BUSINESS WIRE) – AbCellera (Nasdaq: ABCL), a technology company with… Read More
Establishes leadership position in manufacturing and commercialization of rare cannabinoids Positions InMed within large and growing consumer health and wellness cannabinoid markets Transitions InMed into revenue generating company; acquires pipeline… Read More
VANCOUVER, BC – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that Eric. A. Adams, President and… Read More
